Abbonarsi

Structural markers observed with endoscopic 3-dimensional optical coherence tomography correlating with Barrett's esophagus radiofrequency ablation treatment response (with videos) - 18/11/12

Doi : 10.1016/j.gie.2012.05.024 
Tsung-Han Tsai, MS 1, Chao Zhou, PhD 1, Yuankai K. Tao, PhD 1, Hsiang-Chieh Lee, MS 1, Osman O. Ahsen, BS 1, Marisa Figueiredo, PA 2, 3, Tejas Kirtane, MD 2, 3, Desmond C. Adler, PhD 4, Joseph M. Schmitt, PhD 4, Qin Huang, MD 2, 3, James G. Fujimoto, PhD 1, Hiroshi Mashimo, MD, PhD 2, 3,
1 Department of Electrical Engineering & Computer Science, Research Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA 
2 Veterans Affairs Boston Healthcare System, Boston, Massachusetts, USA 
3 Harvard Medical School, Boston, Massachusetts, USA 
4 LightLab Imaging Inc, St. Jude Medical Inc, Westford, Massachusetts, USA 

Reprint requests: Hiroshi Mashimo, MD, PhD, Gastroenterology Section, Veterans Affairs Boston Healthcare System, Harvard School of Medicine, Boston, MA 02130

Riassunto

Background

Radiofrequency ablation (RFA) is effective for treating Barrett's esophagus (BE) but often involves multiple endoscopy sessions over several months to achieve complete response.

Objective

Identify structural markers that correlate with treatment response by using 3-dimensional (3-D) optical coherence tomography (OCT; 3-D OCT).

Design

Cross-sectional.

Setting

Single teaching hospital.

Patients

Thirty-three patients, 32 male and 1 female, with short-segment (<3 cm) BE undergoing RFA treatment.

Intervention

Patients were treated with focal RFA, and 3-D OCT was performed at the gastroesophageal junction before and immediately after the RFA treatment. Patients were re-examined with standard endoscopy 6 to 8 weeks later and had biopsies to rule out BE if not visibly evident.

Main Outcome Measurements

The thickness of BE epithelium before RFA and the presence of residual gland-like structures immediately after RFA were determined by using 3-D OCT. The presence of BE at follow-up was assessed endoscopically.

Results

BE mucosa was significantly thinner in patients who achieved complete eradication of intestinal metaplasia than in patients who did not achieve complete eradication of intestinal metaplasia at follow-up (257 ± 60 μm vs 403 ± 86 μm; P < .0001). A threshold thickness of 333 μm derived from receiver operating characteristic curves corresponded to a 92.3% sensitivity, 85% specificity, and 87.9% accuracy in predicting the presence of BE at follow-up. The presence of OCT-visible glands immediately after RFA also correlated with the presence of residual BE at follow-up (83.3% sensitivity, 95% specificity, 90.6% accuracy).

Limitations

Single center, cross-sectional study in which only patients with short-segment BE were examined.

Conclusion

Three-dimensional OCT assessment of BE thickness and residual glands during RFA sessions correlated with treatment response. Three-dimensional OCT may predict responses to RFA or aid in making real-time RFA retreatment decisions in the future.

Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : BE, CE-D, CE-IM, GEJ, OCT, RFA, 3-D


Mappa


 DISCLOSURE: This work was supported by the Massachusetts Institute of Technology(MIT)/CIMIT Medical Engineering Fellowship (T.H.T.), the Veterans Affairs Boston Healthcare System, NIH grants R01-CA75289-15 (J.G.F. and H.M.), R44CA101067-06 (J.G.F.), and K99-EB010071-01A1 (C.Z.), Air Force Office of Scientific Research grant FA9550-10-1-0063 (J.G.F.) and Medical Free Electron Laser Program grant FA9550-10-1-0551 (J.G.F.). D. Adler and J. Schmitt are full-time employees of Lightlab Imaging Inc, St. Jude Medical. J. Fujimoto receives royalties from intellectual property owned by MIT and licensed to Lightlab Imaging Inc, St. Jude Medical and royalties from intellectual property owned by MIT and licensed to Carl Zeiss Meditec and is a scientific advisor for and has stock options with Optovue, Inc. No other financial relationships relevant to this publication were disclosed.
 If you would like to chat with an author of this article, you may contact Dr Mashimo at hmashimo@hms.harvard.edu.


© 2012  American Society for Gastrointestinal Endoscopy. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 76 - N° 6

P. 1104-1112 - dicembre 2012 Ritorno al numero
Articolo precedente Articolo precedente
  • Clinical features of pharyngeal intraepithelial neoplasias and outcomes of treatment by endoscopic submucosal dissection
  • Takayasu Kuwabara, Toru Hiyama, Shiro Oka, Yuji Urabe, Shinji Tanaka, Masaharu Yoshihara, Koji Arihiro, Fumio Shimamoto, Kazuaki Chayama
| Articolo seguente Articolo seguente
  • Barrett's esophagus: should we burn it all?
  • Andrea May

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.